P2P Group Increases Biometric Detection Range by 166%--Transforming Security, Defence and Aged Care
(CSE: PPB / FSE: 3QG / US: PPBGF)investor@p2p-group.com
Highlights:
Opens new markets in border control, defence, and passive health monitoring
Extends wireless heart rate and breathing detection range from 3m to 8m using standard Wi-Fi
Enables detection of hidden individuals and weapons in vehicles and sealed environments from human or drone-operated devices.
Click to join the public Inturai Telegram Channel https://t.me/inturai
VANCOUVER, BC, June 11, 2025 /CNW/ - P2P Group Ltd. (CSE: PPB) (FSE: 3QG) (US: PPBGF) is pleased to announce a major improvement in its wireless sensing platform, achieving heart rate and breathing detection at distances of up to 8 metres—more than doubling its prior range.
This enhancement strengthens both the SafeWave and StealthWave systems and significantly increases addressable market applications:
Border Security and Customs – Identifying concealed individuals in transport vehicles and closed compartments
National Defence and Tactical Teams – Gathering biometric intelligence without line of sight
Aged Care and Remote Health – Enabling unobtrusive, low-cost, and full room monitoring with no cameras, wearables, or privacy trade-offs
"Expanding the range to 8 metres without adding complexity is a very meaningful leap," said Ed Clarke, CEO of P2P Group. "This capability pushes us into new operational zones where traditional solutions simply can't go."
The Company is advancing IP protection, commercial rollout plans, and customer notifications. Updates will follow as deployment progresses.
About P2P Group
P2P Group is advancing intelligent environments through its proprietary Inturai AI signal sensing technology, transforming sectors including healthcare, defence, policing, emergency services, drones, smart homes, and industrial systems. By leveraging standard Wi-Fi and radio signals, Inturai delivers next-generation spatial intelligence without the need for invasive or specialist hardware. This breakthrough enables safer, smarter spaces across a range of high-impact use cases. To learn more, visit www.p2p-group.com.
This document contains certain forward-looking statements that are based on assumptions as of the date of this news release. Forward-looking statements are frequently characterised by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/p2p-group-increases-biometric-detection-range-by-166transforming-security-defence-and-aged-care-302478448.html
SOURCE P2P Group Limited
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/11/c0687.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Alpha Modus Expands Strategic Patent Licensing Program with VSBLTY Partnership
CORNELIUS, N.C. and PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD), a leading force in AI-driven retail innovation, announced today a definitive licensing agreement with VSBLTY Groupe Technologies Corp. (OTC: VSBGF), a company specializing in AI-based security and retail analytics solutions. This agreement signals a deepening commercial relationship rooted in Alpha Modus' robust patent portfolio."This deal is more than a license—it's validation of our technology's growing adoption in the smart retail ecosystem,' said Tom Gallagher, Chief Revenue Officer of Alpha Modus. 'Our IP continues to drive value not only through enforcement but also through synergistic deployments with next-generation retail platforms like those offered by VSBLTY.' "We're excited to align with Alpha Modus in this meaningful way,' added Jay Hutton, Chief Executive Officer of VSBLTY. 'Their pioneering work in real-time consumer intelligence aligns perfectly with our mission to redefine the retail experience through AI and advanced analytics.' Under the newly signed license agreement, Alpha Modus and VSBLTY are exploring an expansion into a broader partnership. Discussions are underway to integrate VSBLTY and, Shelf Nine LLC, into the Alpha Modus ecosystem as preferred retail media and technology partners. As part of the strategic dialogue, Alpha Modus intends to begin reselling both VSBLTY and Shelf Nine's AI-driven retail display and media solutions, further amplifying the collective market impact. The licensing deal is expected to contribute materially to Alpha Modus' revenue streams while simultaneously broadening the company's footprint in high-traffic commercial environments enhanced by smart technologies. This announcement marks yet another milestone in Alpha Modus' aggressive IP monetization strategy, which includes settlements, licensing, and strategic partnerships across the AI retail tech landscape. For more information and to access Alpha Modus' press room, visit: About Alpha Modus Holdings, Modus Holdings, Inc. (NASDAQ: AMOD) is an AI-first technology company focused on redefining retail environments through intelligent automation, consumer engagement analytics, and data-driven retail solutions. About VSBLTY Headquartered in Philadelphia, VSBLTY (OTCQB: VSBGF) (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF) ('VSBLTY') is the world leader in Artificial Intelligence and real time interpretation of what a CCTV and other cameras see. By utilizing facial recognition, age and gender, VSBLTY's proprietary technology can effectively enhance retail brand engagement and data analytics measurement through customized ads on instore digital displays at point of purchase in real time. This technology has been proven to increase brand sales by over 25%. The firm is also recognized for its leadership role in the growing 'Store as a Medium' movement that enables brands to reach customers with paid media ads when and where buying decisions are being made while producing a new revenue stream for retailers. Most recently, VSBLTY has been building object recognition software to identify products by SKU, at the point of checkout, to integrate this capability into their retail media network offering to retailers and large CPG brands that lack customer information and transaction data at the point of sale. Using its proprietary AI software, and the various data collected using their software, VSBLTY has also developed a range of security solutions that include not only facial recognition but weapon recognition utilizing modern surveillance cameras and legacy CCTV cameras. VSBLTY has the capability to create a proactive security system rather than a reactive security system, providing early warning of threats that can save lives. Data collected through the platform can inform large scale deployments for smart city, private state and federal municipal security programs including border control. Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus's actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus's expectations with respect to future performance. Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Investor Relations - Alpha Modus Holdings, ir@ Follow us on LinkedIn | Follow us on X Investor Relations - VSBLTY Groupe Technologies Corp. Linda Rosanio, 609-472-0877lrosanio@ Harbor AccessJonathan Paterson, A photo accompanying this announcement is available at
Business Upturn
25 minutes ago
- Business Upturn
ZenaTech's ZenaDrone to File Patent and Accelerate Deployment of Counter-UAS Technology on the ZenaDrone 1000 in Response to US Executive Order
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ('ZenaTech'), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces its subsidiary ZenaDrone's intent to file a patent and accelerate the deployment of Counter-Unmanned Aircraft System (Counter-UAS) technology, to be mounted on the company's flagship ZenaDrone 1000 drone platform in response to a new executive order policy directive. Counter-UAS technology refers to tools or systems that can detect, track, or mitigate unauthorized or dangerous drones to protect people, property, and airspace. ZenaDrone's technology for this was originally designed last year but was placed on hold as the company prioritized other commercial and defense applications. However, the recent policy directive on Counter-UAS contained in the June 6th, 2025, White House Executive Order, 'Restoring American Airspace Sovereignty', has clarified the urgency and importance of bringing effective drone defense solutions to market. In response, ZenaDrone is accelerating development and commercialization efforts to meet growing domestic and international demand. Advertisement 'We developed our Counter-UAS system with future threats in mind, and the Executive Order has made it clear that the time to act is now,' said Dr. Shaun Passley, CEO of ZenaTech. 'Integrating this technology into the ZenaDrone 1000 positions us to meet urgent security needs with a smart, autonomous aerial defense platform and be seen as a provider of safe, trusted, and mission-ready solutions.' The company will immediately expand its engineering and defense teams to fast-track R&D, testing, and deployment. The enhanced ZenaDrone 1000 will feature real-time threat detection and neutralization capabilities, making it a viable solution for military, homeland security, and critical infrastructure protection operations. The recent executive order, one of two historic policy directives announced on June 6th, 2025, provides a boost to US drone companies by driving demand for counter-UAS technologies, setting needed federal standards for secure airspace integration, and prioritizing US-made systems over foreign alternatives. The ZenaDrone 1000 is an AI multifunction autonomous drone that is a 12X7-foot rotary-wing octocopter design—built for commercial applications including surveillance, inspection and precision agriculture, as well as for defense. It features a patented foldable-wing design, can carry up to a 40 kg or 88 lbs of payload, and can fly for up to an hour before recharging on its docking station. It can be equipped with a variety of thermal imaging, LiDAR, or multispectral sensors to enable real-time ISR (intelligence, surveillance, and reconnaissance), border patrol, and other defense applications. About ZenaTech ZenaTech (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical business applications. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, health, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech's portfolio of solutions helps drive exceptional operational efficiencies, accuracy, and cost savings. The Company operates through seven global offices in North America, Europe, Taiwan, and UAE, and is growing a DaaS business model and global partner network. About ZenaDrone ZenaDrone, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous business drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for industrial surveillance, monitoring, inspection, tracking, process automation and defense applications. Currently, the ZenaDrone 1000 drone is used for crop management applications in agriculture and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, and the IQ Square is an indoor/outdoor drone designed for land survey and inspections use in commercial and defense sectors. Contacts for more information: Company, Investors and Media: Linda Montgomery ZenaTech 312-241-1415 [email protected] Investors: Michael Mason CORE IR [email protected] Safe Harbor This press release and related comments by management of ZenaTech, Inc. include 'forward-looking statements' within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management's expectations and projections regarding ZenaTech's growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as 'may', 'will', 'should', 'expect', 'plan', 'anticipate', 'aim', 'seek', 'is/are likely to', 'believe', 'estimate', 'predict', 'potential', 'continue' or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech's expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech's ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000 and IQ Nano; ZenaTech's anticipated cash needs and it's needs for additional financing; ZenaTech's intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech's expected business objectives for the next twelve months; ZenaTech's ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
25 minutes ago
- Business Upturn
NetraMark Founder Coauthors New Publication on AI/ML Use in Clinical Trials, Alongside Authors From Leading Global Regulatory Organizations
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the 'Company' or 'NetraMark') (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication that outlines the market opportunity for AI/ML to improve data quality and patient outcomes in clinical development. This manuscript, now available in the Journal of the Society for Clinical Data Management (JSCDM), is titled 'Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Good Clinical Practice Perspectives .' It identifies the ideal conditions and prerequisites for the use of emerging AI applications in clinical trials and the importance of aligning these technologies with Good Clinical Practice (GCP). Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark, contributed to this collaborative effort alongside individuals affiliated with organizations such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Danish Medicines Agency (DKMA), Pfizer, Sanofi, Neurocrine Biosciences, Saama Technologies, Relation Therapeutics, Cognizant Technology Solutions, and Wega Informatik AG. These contributions represent the personal views of the authors and not the official positions of their respective organizations. Drawing on the collective insights of regulators, sponsors, and technology developers, this publication explores the multifaceted landscape of AI/ML applications, where AI can deliver measurable benefits while ensuring compliance, transparency, patient safety, efficiency, accuracy, and overall effectiveness of clinical trials, specifically through seven real-world use cases: Smart Data Query Data Attributability Challenges in Wearable Device Data Enhancing Protocol Deviation Trending External Control Arms Streamlining Complaint Handling Patient Stratification in Diagnosis Patient Enrichment for Placebo/Drug Response Additionally, the manuscript highlights several challenges and ethical considerations facing AI/ML adoption in clinical trial, including: Challenges Generalizability – how well AI models can perform beyond their original training, testing, and validation data Provenance – the decisions, implicit or hidden, that were made in the creation of a model Effective clinical trialist-AI/ML interaction Ethical Considerations Robust, multi-layered privacy controls Trustworthy AI that is lawful, ethical, and technically and socially robust Built for Compliance, Designed for Impact: How NetraAI's Capabilities Align with Industry Needs Built from the ground up to advance the impact that AI can have on clinical trial enrichment, NetraAI goes beyond traditional AI assessments to provide a specialized solution for small or sparse dataset modeling, addressing the key conclusions of the JSCDM manuscript: Explainability and Auditability Data Quality Monitoring and Anomaly Detection Patient Stratification and Enrichment Mitigation of Placebo Response Multi-modal Data Integration Explainability and Auditability Ethical and Regulatory Alignment 'It was an honor to contribute to this significant review alongside respected voices from across the global regulatory and pharmaceutical landscape,' said Dr. Joseph Geraci, Founder, CSO, and CTO of NetraMark. 'NetraMark is committed to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes. Our collective work underscores the opportunities for NetraAI to help set the standards in the pharmaceutical industry and establish the best use of AI/ML and ethical compliance for clinical trial evolution.' This review is available to the public at . About NetraMark NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation including statements regarding the potential use of NetraMark's AI solutions to drive intelligent, patient-centric clinical trial optimization, the optimization of clinical trials by uncovering hidden patient subpopulations, how NetraAI may address the key conclusions of the JSCDM manuscript, the integration of NetraMark's AI as a dedicated solution to advance clinical trial success, NetraMark's commitment to working with sponsors to realize the benefits of AI/ML adoption in traditional clinical trial processes, opportunities for NetraAI to help set standards in the pharmaceutical industry, the establishment of best practices for AI/ML use and ethical compliance, and the advancement of technological capabilities of clinical trial enrichment, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as 'expect', 'likely', 'may', 'will', 'should', 'intend', 'anticipate', 'potential', 'proposed', 'estimate' and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions 'may', 'would' or 'will' happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The CSE does not accept responsibility for the adequacy or accuracy of this release. Contact Information: Swapan Kakumanu – CFO | [email protected] | 403-681-2549 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
